Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 AbbVie's blockade of cheaper Humira options
2 AbbVie's post-Humira stalwarts Skyrizi, Rinvoq performing exactly as hoped, CEO says
3 Global Top Selling Biologics Markets 2021-2030: Humira, Keytruda, Opdivo, Avastin, Rituxan, Stelara, Herceptin, Enbrel
4 Hidradenitis suppurativa ripe for competition with Humira the only approved biologic
5 When Humira Finally Faces Biosimilar Competition, Losses For AbbVie May Not Be As Steep As Expected, Say Analysts
6 AbbVie Posts Strong Second Quarter as Rinvoq Gears Up to Succeed Humira
7 HUMIRA (Adalimumab) Biosimilars Report 2021: Focus on Approved & Launched, Investigational & Research Use, Inactive/Terminated/Withdrawn, Industry/Non-Industry Partnerships
8 Humira's reign as TV ad king is over as AbbVie shifts spending to Rinvoq and Skyrizi
9 Fear not, AbbVie. Sales king Humira might have a graceful fall from biosim attack: analyst
10 Consumers, small businesses, taxpayers need relief from Big Pharma
11 Interchangeable Biosimilars: Insulin Likely First But Humira May Be More Important Precedent
12 AbbVie's biosimilar erosion woes overstated
13 The pros and cons of immune modulating drugs
14 The top 15 blockbuster patent expirations coming this decade
15 Worldwide Biological Safety Testing Industry to 2026
16 Adalimumab Biosimilar Transition Studies Reported at ECCO'21 Congress
17 Humira: Side Effects, Uses, Cost, How to Inject, and More
18 Humira Market Research Report 2021 Elaborate Analysis With Growth Forecast To 2027 – AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals – The Manomet Current
19 Humira: Side effects and what to do about them
20 Humira and dosage: Strengths, forms, when to use, and more
21 Cimzia vs. Humira: What's the difference between them?
22 AbbVie's net revenues rise 33.9% in second quarter of 2021
23 House Committee Issues Blistering Report on AbbVie's Humira Tactics May 18th 2021 By Tony Hagen Article
24 Alberta, Canada, Begins Mandating Switches From Originator to Biosimilar Humira
25 British Columbia Switches From Humira to 5 Biosimilar Versions
26 3 Underrated Warren Buffett Stocks That Are Smart Buys Right Now
27 Humira Dosage: Forms, Strengths, How to Use, and More
28 Top in rheumatology: Humira biosimilars, refractory Lyme arthritis
29 Humira for Crohn's Disease: Safety, Efficacy, and Side Effects
30 Humira Drug / Medicine Information
31 Stelara vs. Humira: Is One of Them Right for You?
32 Alvotech Files Suit to Invalidate Humira Patents
33 HUMIRA (adalimumab) for the Treatment of Ulcerative Colitis
34 Market Crash 2.0: Where to Invest $1,000
35 Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close
36 Drug price inflation stalls as spending for certain products rises
37 Abbvie
38 GAO Report Finds DTC Advertising May Lead to Increased Medicare Spend
39 Skyrizi vs. Humira: Is One of Them Right for You?
40 HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
41 Oxford to study anti-inflammatory drug Humira as potential COVID-19 treatment
42 Competition From Biosimilars Drives Price Reductions For Biologics In The French Single-Payer Health System
43 Johnson & Johnson spotlights safety edge after Stelara's near miss against Humira in Crohn's
44 7 Ways Drug Pricing Legislative Proposals Would Lower Costs for Consumers and Businesses
45 Global Humira Market 2021-2030 Industry Growth by : AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen – Domestic Violence
46 AbbVie Hopefuls Skyrizi and Rinvoq Show Promise in Quest to Succeed Humira
47 Cyltezo Is a Contender for First Interchangeable to Humira, Boehringer Ingelheim Says
48 AbbVie's Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along
49 Cancer drugs show big sales rise in 2020; AbbVie's Humira again tops list
50 Humira: Side effects, cost, uses, and more
51 Vizient Predicts 7.5% Humira Price Increase Before Biosimilars Arrive January 28th 2021 By Tony Hagen Article
52 AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq
53 AbbVie's post-Humira life looks brighter with Skyrizi psoriatic arthritis win
54 Does Medicare cover Humira? Coverage, eligibility, and costs
55 AbbVie Q2 2021 Earnings Preview
56 VIDEO: Stelara, Humira safely, effectively treat CD
57 Humira Bags Another FDA Approval, This Time for Pediatric Ulcerative Colitis
58 AbbVie scores crucial phase 3 wins with Humira follow-up Skyrizi
59 Otezla vs. Humira: How These Drugs Compare
60 AbbVie's plan to push Rinvoq to counter Humira biosimilar surge dampens
61 AbbVie exec details upbeat plan for Rinvoq, Skyrizi as Humira copycats near: analyst
62 Humira Market to Witness Huge Growth by 2026 | AbbVie, Eisai, Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim – The Manomet Current
63 EU Approves Yuflyma, Humira Biosimilar, for Chronic Inflammatory Diseases
64 Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
65 Biden Patent Office Pick Will Shape Fight Over High Drug Prices
66 Adalimumab: Sold Under the Brand Name Humira
67 Interchangeable biosimilars arrive in the US | 2021-07-28
68 7th Circuit Hears Oral Arguments in Humira “Patent Thicket” Antitrust Case
69 Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
70 DOD taps Pharm-Olam for repurposed Humira COVID-19 test
71 Abbvie bets on strong Humira rebound
72 UCB drug first to be recommended in new NICE pathway
73 AbbVie CEO summoned to Congress—again—to answer questions on Humira pricing, patenting
74 AbbVie's last stand: How an Icelandic billionaire's biosimilar has one final shot to dethrone Humira
75 Serum LRG useful biomarker of endoscopic activity in IBD patients on Humira
76 Market Forecast Predicts 3.1% Increase in Hospital Drug Spending
77 Alvotech challenges AbbVie on US Humira exclusivity
78 J&J touts Tremfya win in Humira-resistant psoriatic arthritis patients amid showdown with AbbVie's Skyrizi
79 AbbVie drops Humira TV spend; Sanofi and Regeneron, Novo Nordisk step up on March pharma list
80 UnitedHealthcare, Cigna, Aetna all unveil new policies restricting biologics use
81 AbbVie's Humira Still Number 1 in Drug Sales
82 Humira Improved
83 Quality of Life, Work Appear to Improve for Patients Taking Humira...
84 Previous: Humira Biosimilar AVT02 Accepted for Regulatory Review in US, Europe
85 AbbVie's immunology newbies Skyrizi and Rinvoq pick up the slack from declining Humira, but safety questions dog execs
86 UCB's bimekizumab 'pre-approved' using NICE fast-track scheme
87 AbbVie chases its next golden goose in a post-Humira future with new ulcerative colitis data for Rinvoq
88 Pfizer Expects Covid Vaccine to Bring in $33.5 Billion This Year
89 Autoimmune-disease drugs may reduce vaccine response; antibody treatments ineffective vs Brazil variant
90 This Is Why Humira Isn't AbbVie's Biggest Problem Right Now
91 University of Oxford to test AbbVie's Humira as COVID-19 treatment
92 Thinking About Joining the Dogecoin Craze? Here are 2 Smarter Buys
93 AbbVie faces new patent abuse challenge in latest Humira suit | IAM
94 AbbVie eyes Humira matching move into psoriatic arthritis for immunology follow-up Skyrizi
95 Humira Ups Work Productivity, Reduces Sleep Problems in AS, Study Says
96 It’s the New Year, and pharma companies are already hiking prices for popular drugs
97 Humira manufacturer's efforts to block generic options challenged in court
98 Rinvoq psoriasis delay adds to Abbvie's Humira concerns
99 Humira maker AbbVie slammed for patent use as it ramps up Imbruvica
100 Alvotech Files Suit Against AbbVie to Invalidate Humira Patent Portfolio